62 filings
Page 2 of 4
6-K
fxz9e
12 Jan 23
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
4:30pm
6-K
dymt1386n5crlw1hsyw
10 Nov 22
Current report (foreign)
8:30am
6-K
p6ltsrye6u4z6 4phvm
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
6-K
i4g p3cvvqbvuu
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
tv4ghhqytvln
16 Aug 22
Current report (foreign)
4:43pm
6-K
ab6p0zu9n 2enoq
12 Aug 22
Silence Therapeutics Announces Pricing of Underwritten Offering
6:07am
6-K
24x2lxreh5n ls
11 Aug 22
6-K Q2 2022 Quarterly Results
5:02pm
6-K
k2xvohrxy1pb pt
14 Jun 22
Current report (foreign)
5:20pm
6-K
l30b4r xv
16 May 22
Current report (foreign)
8:31am
6-K
qy9qpwi omrhso
16 May 22
Silence Therapeutics plc Notice of Annual General Meeting
8:30am
6-K
dzmsnwj
25 Apr 22
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
8:31am
6-K
sqvrs4coikso1v1tl17
4 Apr 22
Current report (foreign)
8:31am
6-K
sklswj 45t3eeek
23 Mar 22
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
8:30am
6-K
33lqq8
22 Feb 22
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
6:52am
6-K
vddoa zyj2kb
9 Feb 22
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study
7:30am
6-K
9duti6s66t4rxeumoe
13 Dec 21
Current report (foreign)
6:01am
6-K
r5lbosm7x7m icpek
26 Nov 21
Current report (foreign)
6:23am
6-K
ihc216
16 Nov 21
Current report (foreign)
6:03am
6-K
1onyc0pt73r2doao9w
1 Nov 21
Results of General Meeting
5:30pm
6-K
itzxr3q41
21 Oct 21
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
8:45am